Neuphoria Therapeutics (NASDAQ:NEUP) Stock Rating Lowered by Wall Street Zen

Neuphoria Therapeutics (NASDAQ:NEUP) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

Several other research firms have also issued reports on NEUP. Weiss Ratings lowered shares of Neuphoria Therapeutics from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Wednesday, October 8th. Maxim Group raised their price target on shares of Neuphoria Therapeutics from $18.00 to $35.00 and gave the stock a “buy” rating in a research report on Thursday, September 11th. Finally, HC Wainwright restated a “buy” rating and issued a $21.00 price target on shares of Neuphoria Therapeutics in a research report on Tuesday, August 26th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $28.00.

Neuphoria Therapeutics Price Performance

Shares of NEUP opened at $4.55 on Friday. The company has a market capitalization of $10.74 million, a PE ratio of 0.86 and a beta of 0.51. Neuphoria Therapeutics has a one year low of $2.16 and a one year high of $21.40. The company’s fifty day moving average price is $11.88 and its 200 day moving average price is $8.52.

Neuphoria Therapeutics (NASDAQ:NEUP) last posted its quarterly earnings results on Monday, September 29th. The company reported ($5.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($5.23). The business had revenue of ($0.01) million for the quarter. Analysts anticipate that Neuphoria Therapeutics will post -1.56 earnings per share for the current year.

Insider Buying and Selling at Neuphoria Therapeutics

In other Neuphoria Therapeutics news, major shareholder Lynx1 Capital Management Lp bought 639,110 shares of the firm’s stock in a transaction dated Tuesday, October 21st. The shares were acquired at an average cost of $5.14 per share, for a total transaction of $3,285,025.40. Following the transaction, the insider owned 875,328 shares in the company, valued at approximately $4,499,185.92. The trade was a 270.56% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 0.69% of the company’s stock.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor.